One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFL...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Med
Autori principali: Vedtofte, Louise, Bahne, Emilie, Foghsgaard, Signe, Bagger, Jonatan I., Andreasen, Camilla, Strandberg, Charlotte, Gørtz, Peter M., Holst, Jens J., Grønbæk, Henning, Svare, Jens A., Clausen, Tine D., Mathiesen, Elisabeth R., Damm, Peter, Gluud, Lise L., Knop, Filip K., Vilsbøll, Tina
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7601647/
https://ncbi.nlm.nih.gov/pubmed/33036179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9103213
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi